Ophthalmology
Overview
We are exploring the potential of Bicycles in ophthalmology in partnership with Oxurion. Phase 2 clinical trials are ongoing with THR-149 in patients suffering from diabetic macular edema.
The pharmacological and physicochemical characteristics of Bicycles could make them well-suited for ophthalmology indications, as they are retained in the eye for long periods of time. Bicycle partnered with ophthalmology experts at Oxurion, to develop THR-149, a plasma kallikrein inhibitor identified by Bicycle Therapeutics, for the treatment of diabetic macular edema (DME).
A Phase 1 clinical study of THR-149 in patients with DME was completed in July 2019 and positive top-line results were announced, showing that THR-149 was well-tolerated and safe, with improvements to patients’ best corrected visual acuity (BCVA) starting at Day 1 and maintained out to Day 90.
As of June 2021, Oxurion had completed enrolment in Part A of its two-part Phase 2 study. The results, reported in February 2022, were in line with what was observed in the Phase 1 study. Bicycle is eligible to receive milestones and royalty payments from the collaboration. More on the Phase 1 results can be read here.
